ADHD medication, heart health and blood pressure

Questions about the heart come up in almost every conversation about ADHD medication, and they deserve a straight account of the evidence. The honest position sits between two overstatements. ADHD medication has not been shown to cause heart disease, and it has not been proven free of cardiovascular risk. What exists is a known small effect on blood pressure and pulse, one large long-term study showing an association, and clear label instructions about screening and monitoring.

The short-term effect is well established

Stimulant labels describe the effect directly. The current FDA labels for both an amphetamine product and a methylphenidate product state that CNS stimulants may cause an increase in blood pressure, with a mean increase of approximately 2 to 4 mm Hg, and an increase in heart rate, with a mean of approximately 3 to 6 beats per minute. The methylphenidate label adds that some patients may have larger increases.

Those are averages across trial participants. An average that small can hide individuals whose readings rise more, which is the reason the labels tell prescribers to monitor every patient for hypertension and tachycardia (a fast heart rate).

Non-stimulants are not exempt. The label for atomoxetine says heart rate and blood pressure should be measured at baseline, after dose increases and periodically during treatment.

What the long-term study found

The most cited long-term evidence is a study by Zhang and colleagues published in JAMA Psychiatry (online November 2023, issue of February 2024). It used Swedish national registers covering 278,027 people aged 6 to 64 with ADHD. The researchers identified 10,388 people who developed cardiovascular disease and compared each with matched controls, 51,672 in all, over a median follow-up of 4.1 years.

An odds ratio of 1.00 means no difference. A figure of 1.27 means the odds were 27% higher than in the comparison group.

Across the whole period, each additional year of use was associated with about 4% higher odds (adjusted odds ratio 1.04, 95% confidence interval 1.03 to 1.05). The increase was concentrated in the first three years, at about 8% per year.

The signal came from two diagnoses. For hypertension, the adjusted odds ratio was 1.72 at three to five years of use and 1.80 beyond five years. For arterial disease it was 1.65 at three to five years, and the result beyond five years was not statistically significant.

News coverage reported no significant link with arrhythmia, heart failure, ischemic heart disease, thromboembolism or stroke. That detail comes from secondary reports and could not be confirmed from the study abstract for this guide, so treat it with caution.

How to read those numbers

• Association is not causation. This was an observational case-control study. People who stay on medication for years may differ from those who do not in ways the researchers could not fully adjust for.
• Relative odds are not absolute risk. The table says how the odds compared between groups. It does not say how likely any one person is to develop cardiovascular disease, which depends on that person's own risk factors.
• The age range was wide. The study included people from 6 to 64, so the results are not specific to adults.
• The finding fits the known mechanism. A medication that nudges blood pressure upward, taken for years, would be expected to show up as more diagnosed hypertension. That is an argument for checking blood pressure, and it is something a prescriber can act on.

The other side of the ledger

Risk has to be set against what treatment does. A separate Swedish study by Li and colleagues, published in JAMA in March 2024, followed 148,578 people aged 6 to 64 for two years after a new ADHD diagnosis. Starting medication was associated with lower all-cause mortality: 39.1 deaths per 10,000 people compared with 48.1 (hazard ratio 0.79). Deaths from unnatural causes, such as accidents and poisoning, were lower (hazard ratio 0.75). The difference in deaths from natural causes was not statistically significant.

The same caution applies. That study was observational, the median age at diagnosis was 17.4, and it shows an association. It does not show that medication prevents death.

Read together, the two studies do not point to a simple answer. They describe a treatment with measurable benefits and a modest long-term blood pressure signal, which is why monitoring matters. Does ADHD treatment work in adults? covers the efficacy trials.

What screening and monitoring involve

FDA labels set out the basic steps, and they are the same whether care is in person or by video.

Before starting

• A cardiac history. Stimulant labels tell prescribers to assess for the presence of cardiac disease with a careful history, a family history of sudden death or ventricular arrhythmia, and a physical exam.
• Disclosure of known heart conditions. The labels say to avoid stimulant use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease or other serious cardiac disease.
• A baseline blood pressure and pulse. The atomoxetine label specifies a baseline measurement, and a starting reading is what later readings are compared with.

During treatment

• Regular blood pressure and pulse checks. One stimulant label words this as monitoring "at appropriate intervals." The interval is the prescriber's judgment.
• Rechecks after a dose change. The atomoxetine label calls for measurement after dose increases.
• Reporting symptoms. The atomoxetine label says patients who develop symptoms suggestive of cardiac disease during treatment should have a prompt cardiac evaluation. Tell your prescriber promptly about any symptom that worries you, and call 911 in an emergency.

If your prescriber sees you by video, ask how blood pressure readings will be collected. Ask, for example, whether a home cuff reading or a recent measurement from your primary care office is acceptable.

Questions to bring to a prescriber

1. Does anything in my history or my family's history change which medication you would consider?
2. What was my blood pressure and pulse before starting, and what readings would concern you?
3. How often do you want readings, and how should I send them?
4. Should my primary care clinician be told that I am starting this medication?
5. If my blood pressure rises, what are the options?

Nothing here is individual medical advice. People with a heart condition, high blood pressure or a family history of early cardiac death should raise it before starting any ADHD medication.

Where to go next

Monitoring only works if follow-up actually happens. The next article, how often you need follow-up visits for ADHD medication in New York, compares visit schedules and what New York's prescription rules imply for them. For the medication classes, see ADHD medications approved for adults in 2026. The service page on adult ADHD treatment describes medication management in practice.